deNovo Health and Aesthetics

deNovo Health and Aesthetics has served the Dallas, TX metropolitan area since 1997, operating as an integrated medical wellness and aesthetic practice that combines hormone optimization, peptide-based weight management, and cosmetic procedures under physician supervision. With over two decades of clinical experience in the Dallas market, the practice maintains a 4.9-star rating across 337 Google reviews, reflecting consistent patient outcomes in metabolic health and age management medicine. The clinic requires in-person consultations for all new patients, allowing providers to conduct comprehensive metabolic panels, body composition analysis, and medical history reviews before initiating any peptide or hormone protocols.

The practice has incorporated Semaglutide into its weight management protocols, utilizing this GLP-1 receptor agonist for patients who meet clinical criteria for peptide-assisted weight loss. Semaglutide therapy at deNovo Health and Aesthetics follows evidence-based dosing schedules with weekly subcutaneous administration, combined with nutritional counseling and metabolic monitoring throughout treatment duration. The Dallas clinic structures Semaglutide programs to include baseline laboratory work measuring fasting glucose, hemoglobin A1c, lipid panels, and thyroid function, with follow-up testing at regular intervals to track metabolic improvements beyond scale weight. Patients receive instruction on proper injection technique, refrigeration requirements, and recognition of gastrointestinal side effects that may require dose adjustment, ensuring safe administration of this peptide therapy outside clinical settings.

Hormone replacement therapy represents a core competency at deNovo Health and Aesthetics, with protocols addressing testosterone deficiency in men, estrogen and progesterone optimization in perimenopausal and postmenopausal women, and thyroid hormone balancing for patients with subclinical hypothyroidism. The Dallas providers utilize bioidentical hormone formulations when clinically appropriate, with delivery methods ranging from subcutaneous pellets to topical creams and injectable preparations based on patient pharmacokinetics and preference. Hormone protocols integrate with the clinic's aesthetic services, as optimized endocrine function supports skin quality, body composition, and recovery from cosmetic procedures. The practice monitors hormone patients through serial laboratory testing at three-month intervals during dose titration and semi-annually once therapeutic levels stabilize.

Aesthetic treatments at the Dallas location include neuromodulator injections, dermal fillers, laser skin resurfacing, and body contouring technologies, all performed by medical providers trained in facial anatomy and injection techniques. The integration of aesthetic services with metabolic and hormone optimization allows deNovo Health and Aesthetics to address both internal health markers and external appearance concerns within a single practice setting. Patients pursuing Semaglutide for weight loss often combine peptide therapy with skin tightening procedures to address changes in facial volume or body contour that accompany significant fat reduction. This coordinated approach requires the in-person consultation model the clinic maintains, as providers assess candidacy for multiple treatment modalities during initial evaluations.

deNovo Health and Aesthetics operates exclusively through scheduled in-person appointments at its Dallas facility, requiring patients to visit the clinic for initial consultations, follow-up assessments, and treatment administration when applicable. This model allows for direct provider-patient interaction, hands-on physical examinations, and immediate access to on-site laboratory collection and diagnostic equipment. The practice does not offer telehealth consultations or remote peptide prescribing, positioning itself for patients in the Dallas-Fort Worth metroplex who prefer face-to-face medical care and the accountability of regular clinic visits. The longevity of the practice since 1997 has established referral relationships with Dallas-area physicians, creating a network for co-management of patients with complex metabolic conditions requiring both primary care oversight and specialized peptide or hormone interventions.